Acura Pharmaceuticals, Inc. Logo Image

Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. Banner Image

Most Recent Annual Report

2019 Annual Report and Form 10K

Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. does not currently have any hardcopy reports on Click the button below to request a report when hardcopies become available.

Archived Annual Reports

About Acura Pharmaceuticals, Inc.

11-50 Employees
Based in Palatine, Illinois

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies. The Company’s product, Oxecta Tablets CII (Oxecta) represents the immediate-release oxycodone product approved by the United States Food and Drug Administration that applies its Aversion Technology. Aversion is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules designed to address some common methods of product tampering associated with abuse. As of December 31, 2011, the Company was also developing Nexafed, an over-the-counter (OTC) immediate-release pseudoephedrine HCl tablet, utilizing its Impede Technology. On January 23, 2012, Oxecta was made commercially available by Pfizer Inc. (Pfizer). On June 17, 2011, Oxecta was approved for marketing by the United States Food and Drug Administration.

NASDAQ (See More NASDAQ Companies)
Drug Delivery (See More Drug Delivery Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol